5,708 Shares in Sanofi (NASDAQ:SNY) Purchased by SVB Wealth LLC

SVB Wealth LLC purchased a new position in Sanofi (NASDAQ:SNY) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 5,708 shares of the company’s stock, valued at approximately $275,000.

Several other institutional investors have also modified their holdings of SNY. Charles Schwab Investment Management Inc. increased its holdings in Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors increased its holdings in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after buying an additional 751 shares during the last quarter. Geode Capital Management LLC increased its holdings in Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after buying an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, Kentucky Trust Co bought a new stake in Sanofi in the fourth quarter valued at about $436,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Trading Up 2.5 %

NASDAQ:SNY opened at $59.15 on Thursday. Sanofi has a 1 year low of $45.22 and a 1 year high of $59.19. The stock has a market cap of $150.11 billion, a price-to-earnings ratio of 23.76, a PEG ratio of 1.01 and a beta of 0.57. The business has a fifty day moving average of $52.22 and a 200-day moving average of $52.68. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.